Literature DB >> 19543728

Temozolomide in malignant gliomas: current use and future targets.

J Lee Villano1, Tara E Seery, Linda R Bressler.   

Abstract

Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19543728     DOI： 10.1007/s00280-009-1050-5

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  74 in total

1.  Temozolomide (Temodar).

Authors:  J R Wesolowski; P Rajdev; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-10       Impact factor: 3.825

2.  Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.

Authors:  Matt Williams; Zi Wei Liu; David Woolf; Sarah Hargreaves; Vasiliki Michalarea; Rebecca Menashy; Ishminder Kooner; Elena Wilson
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-27       Impact factor: 4.553

3.  Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles.

Authors:  M Ganau
Journal:  Clin Transl Oncol       Date:  2013-09-27       Impact factor: 3.405

4.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Authors:  Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

5.  Phenotypic and functional characterization of Glioblastoma cancer stem cells identified through 5-aminolevulinic acid-assisted surgery [corrected].

Authors:  Elena Rampazzo; Alessandro Della Puppa; Chiara Frasson; Giusy Battilana; Sara Bianco; Renato Scienza; Giuseppe Basso; Luca Persano
Journal:  J Neurooncol       Date:  2014-01-09       Impact factor: 4.130

6.  MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.

Authors:  Er Nie; Xin Jin; Weining Wu; Tianfu Yu; Xu Zhou; Zhumei Shi; Junxia Zhang; Ning Liu; Yongping You
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

7.  Cerebral aspergillosis within new tumour site presents as incidental new brain lesion in patient receiving temozolomide for glioblastoma multiforme.

Authors:  Shiyuan Anabeth Liu; Timothy Sullivan; Clare Bryce; Amy M Chan; Salvatore Cilmi
Journal:  BMJ Case Rep       Date:  2019-05-31

8.  Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate.

Authors:  Tânia Capelôa; Francisco Caramelo; Carlos Fontes-Ribeiro; Célia Gomes; Ana P Silva
Journal:  Neurotox Res       Date:  2014-03-21       Impact factor: 3.911

9.  A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.

Authors:  Zhi Sheng; Li Li; Lihua J Zhu; Thomas W Smith; Andrea Demers; Alonzo H Ross; Richard P Moser; Michael R Green
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

10.  Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report.

Authors:  Asim Jamal Shaikh; Nehal Masood
Journal:  J Med Case Rep       Date:  2010-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.